

10522227a

G4:[*1],[*2],[*3],[*4],[*5],[*6],[*7],[*8],[*9]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
38:Atom 39:Atom 40:Atom 49:CLASS 50:Atom 51:Atom 52:Atom 53:Atom 54:Atom
55:Atom 56:Atom 57:Atom 58:Atom 59:Atom 60:Atom 61:Atom 62:Atom 63:Atom
66:CLASS 67:CLASS 69:CLASS 70:CLASS 71:CLASS 72:CLASS 75:CLASS 76:Atom
77:Atom 78:Atom 79:Atom 81:CLASS

L1 STRUCTURE uploaded

=> d

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 18:21:58 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 841 TO ITERATE

100.0% PROCESSED 841 ITERATIONS
SEARCH TIME: 00.00.01

43 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 15081 TO 18559
PROJECTED ANSWERS: 467 TO 1253

L2 43 SEA SSS SAM L1

=> s 11 full

FULL SEARCH INITIATED 18:22:02 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 16157 TO ITERATE

100.0% PROCESSED 16157 ITERATIONS
SEARCH TIME: 00.00.01

898 ANSWERS

L3 898 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	172.31

FILE 'CAPLUS' ENTERED AT 18:22:06 ON 08 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Karen Cheng

10522227a

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Feb 2007 VOL 146 ISS 7
FILE LAST UPDATED: 7 Feb 2007 (20070207/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13
L4 43 L3

=> fil stng

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.47	172.78

FULL ESTIMATED COST

FILE 'STNGUIDE' ENTERED AT 18:22:24 ON 08 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Feb 2, 2007 (20070202/UP).

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
1.02	173.80

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 18:32:38 ON 08 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 FEB 2007 HIGHEST RN 919834-45-0
DICTIONARY FILE UPDATES: 7 FEB 2007 HIGHEST RN 919834-45-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when

Karen Cheng

10522227a

Search for 

conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10522227b.str

with


W

R⁵

X and

R³ defined

R³- phenyl or thiophenyl



10522227a

exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 5-97 6-7 6-10 7-8 8-9 9-10 10-98 11-12 11-15
12-13 12-99 13-14 14-15 16-17 16-20 16-101 17-18 18-19 19-20 21-22 21-25
21-49 22-23 23-24 24-25 25-102 26-27 26-30 27-28 28-29 29-30 29-103
31-32 31-35 32-33 32-104 33-34 34-35 36-37 36-40 37-38 38-39 39-40
39-105 50-69 51-81 52-66 53-67 54-70 55-72 56-60 56-57 56-76 57-58 57-79
58-59 58-61 59-60 59-63 61-62 62-63 62-106 70-71 71-72 71-75 76-77
77-78 78-79 83-84 83-87 84-85 85-86 86-87
normalized bonds :
50-51 50-55 51-52 52-53 53-54 54-55 88-89 88-93 89-90 90-91 91-92 92-93
isolated ring systems :
containing 50 :

G1:H,CH3

G2:S,N

G3:X,H,CH3,N

G4:[*1],[*2],[*3],[*4],[*5],[*6],[*7],[*8],[*9]

G5:[*10],[*11]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
38:Atom 39:Atom 40:Atom 49:CLASS 50:Atom 51:Atom 52:Atom 53:Atom 54:Atom
55:Atom 56:Atom 57:Atom 58:Atom 59:Atom 60:Atom 61:Atom 62:Atom 63:Atom
66:CLASS 67:CLASS 69:CLASS 70:CLASS 71:CLASS 72:CLASS 75:CLASS 76:Atom
77:Atom 78:Atom 79:Atom 81:CLASS 83:Atom 84:Atom 85:Atom 86:Atom 87:Atom
88:Atom 89:Atom 90:Atom 91:Atom 92:Atom 93:Atom 97:CLASS 98:CLASS 99:CLASS
101:CLASS 102:CLASS 103:CLASS 104:CLASS 105:CLASS 106:CLASS

L5 STRUCTURE UPLOADED

=> d

L5 HAS NO ANSWERS

L5 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 18:21:08 ON 08 FEB 2007)

FILE 'REGISTRY' ENTERED AT 18:21:37 ON 08 FEB 2007

L1 STRUCTURE UPLOADED

L2 43 S L1

L3 898 S L1 FULL

Karen Cheng

10522227a

FILE 'CAPLUS' ENTERED AT 18:22:06 ON 08 FEB 2007
L4 43 S L3

FILE 'STNGUIDE' ENTERED AT 18:22:24 ON 08 FEB 2007

FILE 'REGISTRY' ENTERED AT 18:32:38 ON 08 FEB 2007
L5 STRUCTURE UPLOADED

=> s 15 full sub=13
FULL SUBSET SEARCH INITIATED 18:33:12 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 898 TO ITERATE

100.0% PROCESSED 898 ITERATIONS 596 ANSWERS
SEARCH TIME: 00.00.01

L6 596 SEA SUB=L3 SSS FUL L5

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
41.10 214.90

FILE 'CAPLUS' ENTERED AT 18:33:19 ON 08 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Feb 2007 VOL 146 ISS 7
FILE LAST UPDATED: 7 Feb 2007 (20070207/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:


<http://www.cas.org/infopolicy.html>

=> s 16
L7 7 L6

=> d ibib abs~hitstr tot

Karen Cheng

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006349551 CAPLUS
 DOCUMENT NUMBER: 145:62826
 TITLE: Synthesis of imidazole based p38 MAP (mitogen-activated protein) kinase inhibitors under buffered conditions
 AUTHOR(S): Magnus, Nicholas A.; Diserod, William D.; Nevill, C. Richard, Jr.; Wepsic, James P.
 CORPORATE SOURCE: Chemical Product Research and Development Division, Eli Lilly and Company, Indianapolis, IN, 46285, USA
 SOURCE: Organic Process Research & Development (2006), 10(3), 556-560
 CODEN: OPRDFK; ISSN: 1083-6160
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Chemical developed to give access to multigram quantities of imidazole 479754 and several related analogs, e.g., I (R1 = H or F) for Eli Lilly's p38 MAPK program targeting therapies to address inflammation was described. The mols. of interest had an iso-Pr sulfonyl group present on the 2-aminoimidazole heterocycle that was found to be labile when heated in polar solvents and/or exposed to high or low pH. Due to this instability issue, the syntheses of the target mols. required optimizing Sonogashira reaction conditions, employing a buffered oxidative method to produce α -diones, developing buffered reaction conditions to generate imidazoles, and developing final recrystn. conditions.

IT 660433-80-7P 890653-92-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of (benzimidazolyl)imidazoles for use as p38 MAP kinase inhibitors via Sonogashira coupling of (aryl)acetylenes with (iodo)benzimidazoles followed by oxidation with KMnO4 and heterocyclization with (aryl)aldehydes and NH4OAc)

RN 660433-80-7 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 890653-92-6 CAPLUS
 CN Ethanol, compd. with 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 660433-80-7
 CMF C25 H21 F2 N5 O2 S



CM 2


CRN 64-17-5
 CMF C2 H6 O

H₃C—CH₂—OH


IT 660433-04-5P 660433-13-6P 660433-30-7P
 660433-34-1P 849064-43-3P 890653-93-7P
 890653-94-8P 890653-96-0P 890653-97-1P
 890653-98-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of (benzimidazolyl)imidazoles for use as p38 MAP kinase inhibitors via Sonogashira coupling of (aryl)acetylenes with (iodo)benzimidazoles followed by oxidation with KMnO4 and heterocyclization with (aryl)aldehydes and NH4OAc)

RN 660433-04-5 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-(2-cyclohexyl-5-phenyl-1H-imidazol-4-yl)-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 methylethylsulfonyl)- (9CI) (CA INDEX NAME)




RN 660433-13-6 CAPLUS
 CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-[5-phenyl-2-[2-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 660433-30-7 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-[2-(2-chloro-6-fluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 660433-29-4
 CMF C25 H21 Cl F N5 O2 S



CM 2

CRN 75-75-2
 CMF C H4 O3 S


L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 660433-34-1 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-[2-[2-fluoro-6-(trifluoromethyl)phenyl]-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 660433-33-0
 CMF C26 H21 F4 N5 O2 S



CM 2

CRN 75-75-2
 CMF C H4 O3 S



RN 849064-43-3 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-[5-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 849064-42-2
 CMF C23 H25 F2 N5 O2 S

1052227a

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 890653-93-7 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 660433-80-7
CMF C25 H21 F2 N5 O2 S



CM 2


L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CRN 75-75-2
CMF C H4 O3 S



RN 890653-94-8 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(4-chlorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 660432-82-6
CMF C25 H22 Cl N5 O2 S



CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 890653-96-0 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2-chloro-6-fluorophenyl)-5-(2,4-difluorophenyl)-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 890653-95-9
CMF C25 H19 Cl F3 N5 O2 S

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 890653-97-1 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(1-methylethyl)-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 660433-95-4
CMF C22 H25 N5 O2 S



CM 2

CRN 75-75-2
CMF C H4 O3 S


L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 890653-98-2 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(1,1-dimethylethyl)-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 660433-06-7
CMF C23 H27 N5 O2 S



CM 2

CRN 75-75-2
CMF C H4 O3 S





REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Karen Cheng

L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:962247 CAPLUS
 DOCUMENT NUMBER: 143:266919
 TITLE: Preparation of benzimidazole compounds as p38 kinase inhibitors for the treatment of cancer
 INVENTOR(S): Bonjouklian, Rosanne; Dally, Robert Dean; De Dios, Alfonso; Del Prado Catalina, Miriam Filadelfa; Dominguez-Fernandez, Carmen; Jaramillo Aguado, Carlos; Lopez de Uralde-Garmendia, Beatriz; Montero Salgado, Carlos; Shepherd, Timothy Alan
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 85 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE						
WO 2005090380	A1	2005-US24	20050121							
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW R: BW, GH, GM, KE, LS, MW, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, CZ, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	EP 1720862	A1	20061115	EP 2005-711246	20050121					
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR	PRIORITY APPLN. INFO.:	EP 2004-380022	A	20040203	US 2004-563399P	P	20040419	WO 2005-US24	W	20050121

OTHER SOURCE(S): MARPAT 143:266919
GI



AB Benzimidazole compds. and their analogs I [wherein W = certain N-containing

L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 863606-52-4 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-(1-methyl-4-phenyl-1H-imidazol-5-yl)-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)


RN 863606-88-6 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-[3-(2,4-difluorophenyl)-1H-pyrazol-4-yl]-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)

RN 863606-90-0 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-[1-(2-fluorophenyl)-3-phenyl-1H-pyrazol-4-yl]-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 five-membered heterocyclic: Y = N, CH, CNH2 or CMe; R = alkyl, Ph, benzyl, etc., and pharmaceutically acceptable salts thereof], such as II, were prepd. as inhibitors of kinases, esp. p38 kinases. Exemplified compds. I showed inhibition for p38 kinase and suppression of TNF- both in vitro and in vivo with IC50 values of \leq 5 mM, < 100 nM and < 100 mg/kg, resp. Other biol. activities were also evaluated. Therefore, I and their pharmaceutical compns. are potentially useful for treating a disease or condition capable of being improved or prevented by inhibition of p38 kinase, such as cancer.

IT 863606-33-1P 863606-38-6P 863606-43-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (inhibitor; preparation of benzimidazole compds. as p38 kinase inhibitors for the treatment of cancer)

RN 863606-33-1 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-[2-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl]-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 863606-38-6 CAPLUS
 CN 1H-Benzimidazol-2-amine, 1-(2-methylpropyl)-6-(5-phenyl-1H-1,2,3-triazol-4-yl)- (9CI) (CA INDEX NAME)



RN 863606-43-3 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-[5-(2,4-difluorophenyl)-2-methyl-1H-imidazol-4-yl]-1-(1,2-dimethylpropyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 863605-50-0P 863605-51-0P 863605-52-1P
 863605-53-2P 863605-54-3P 863605-55-4P
 863605-56-5P 863605-57-6P 863605-58-7P
 863605-59-8P 863605-60-1P 863605-61-2P
 863605-62-3P 863605-63-4P 863605-64-5P
 863605-65-6P 863605-66-7P 863605-67-8P
 863605-68-9P 863605-69-0P 863605-72-5P
 863605-75-8P 863605-76-9P 863605-81-6P
 863605-83-8P 863605-85-0P 863605-87-2P
 863605-88-3P 863605-90-7P 863605-92-9P
 863605-94-1P 863605-95-2P 863605-96-3P
 863605-98-5P 863606-00-2P 863606-02-4P
 863606-04-6P 863606-06-8P 863606-07-9P
 863606-08-0P 863606-09-1P 863606-10-4P
 863606-11-5P 863606-12-6P 863606-13-7P
 863606-15-9P 863606-17-1P 863606-19-3P
 863606-21-7P 863606-23-9P 863606-25-1P
 863606-27-3P 863606-28-4P 863606-29-5P
 863606-30-8P 863606-32-0P 863606-34-2P
 863606-35-3P 863606-36-4P 863606-37-5P
 863606-40-0P 863606-41-1P 863606-44-4P
 863606-46-6P 863606-48-8P 863606-50-2P
 863606-51-3P 863606-53-5P 863606-56-8P
 863606-57-9P 863606-60-4P 863606-61-5P
 863606-63-7P 863606-65-9P 863606-67-1P
 863606-69-3P 863606-71-7P 863606-73-9P
 863606-75-1P 863606-77-3P 863606-79-5P
 863606-81-9P 863606-83-1P 863606-85-3P
 863606-85-5P 863606-89-7P 863606-91-1P
 863606-92-2P 863606-95-5P 863606-99-8P
 863607-00-5P 863607-02-7P 863607-04-9P
 863607-06-1P 863607-08-3P 863607-10-7P
 863607-12-9P 863607-13-0P 863607-15-2P
 863607-17-4P 863607-19-6P 863607-21-0P
 863607-22-1P 863607-24-3P 863607-26-5P
 863607-28-7P 863607-29-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (inhibitor; preparation of benzimidazole compds. as p38 kinase inhibitors for the treatment of cancer)


RN 863605-50-9 CAPLUS
 CN 1H-Benzimidazol-2-amine, 1-cyclopentyl-6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 863605-51-0 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-phenyl- (9CI) (CA INDEX NAME)




RN 863605-52-1 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 863605-53-2 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-(2,5-diphenyl-1H-imidazol-4-yl)-1-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 863605-54-3 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-(cyclopropylmethyl)-6-[2-(2,6-difluorophenyl)-5-




RN 863605-58-7 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 863605-59-8 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-ethyl- (9CI) (CA INDEX NAME)




RN 863605-60-1 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-butyl-6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 863605-61-2 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-(2,2-dimethylpropyl)- (9CI) (CA INDEX NAME)




RN 863605-55-4 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 863605-56-5 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-propyl- (9CI) (CA INDEX NAME)




RN 863605-57-6 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-propyl- (9CI) (CA INDEX NAME)




RN 863605-62-3 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 863605-63-4 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-(cyclohexylmethyl)-6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 863605-64-5 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(1,1-dimethylethyl)-5-phenyl-1H-imidazol-4-yl]-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 863605-65-6 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(1-methylethyl)-5-phenyl-1H-imidazol-4-yl]-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 863607-28-7 CAPLUS
 CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-methyl-1-(2-methylpropyl)-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 863607-27-6
 CMF C21 H21 F N4



CM 2



CRN 75-75-2
 CMF C H4 O3 S




RN 863607-29-8 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)

REFERENCE COUNT:


5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



IT 863605-41-8P 863606-58-0P 863606-59-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of benzimidazole compds. as p38 kinase inhibitors for the treatment of cancer)
 RN 863605-41-8 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-[3-(2,4-difluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 863606-58-0 CAPLUS
 CN Acetamide, N-[6-(1-methyl-4-phenyl-1H-imidazol-5-yl)-1-(2-methylpropyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 863606-59-1 CAPLUS
 CN Acetamide, N-[6-(2-bromo-1-methyl-4-phenyl-1H-imidazol-5-yl)-1-(2-

ACCESSION NUMBER: 2005-159128 CAPLUS
 DOCUMENT NUMBER: 142:348138
 TITLE: Design of Potent and Selective 2-Aminobenzimidazole-Based p38α MAP Kinase Inhibitors with Excellent In Vivo Efficacy
 AUTHOR(S): de Dios, Alfonso; Shih, Chuan; Lopez de Uralde, Beatriz; Sanchez, Concepcion del Prado, Miriam; Cabrejas, Luisa M.; Martin, Plete, Silvia; Blanco-Urgoiti, Jaime; Lorite, Maria Jose; Nevill, C. Richard, Jr.; Bonjouklian, Rosanne; York, Jeremy; Vieth, Michal; Wang, Yong; Magnus, Nicholas; Campbell, Robert M.; Anderson, Bryan D.; McCann, Dennis J.; Giera, Deborah D.; Lee, Paul A.; Schultz, Richard M.; Li, Li C.; Johnson, Lea M.; Wolos, Jeffrey A.; Lilly S.A., Eli Lilly and Co., Alcobendas, Madrid, Spain
 CORPORATE SOURCE: 28108, Spain
 SOURCE: Journal of Medicinal Chemistry (2005), 48(7), 2270-2273
 PUBLISHER: CODEN: JCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: American Chemical Society
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 142:348138
 AB We report the design and discovery of a 2-aminoimidazole-based series of potent and highly selective p38α inhibitors. The lead compound had low-nanomolar activity in both ATP competitive enzyme binding and inhibition of TNFα release in macrophages. Compound showed excellent pharmacokinetic properties and oral activity in the rat collagen induced arthritis model. Comparison with other p38 reference compounds. A SAR strategy to address CyP3A4 liability is also described.
 IT 660432-75-7P 660432-77-9P 660433-83-0P
 660433-87-4P 660433-94-3P 660434-06-0P
 660435-18-7P 660435-22-3P 660435-29-0P
 849064-41-1P 849064-43-3P 849064-45-5P
 849064-46-6P
 RL: PAC (Pharmacological activity); PIK (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (design of potent and selective 2-aminoimidazole-based p38α MAP kinase inhibitors with excellent in vivo efficacy)
 RN 660432-75-7 CAPLUS
 CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-(5-phenyl-1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)



RN 660432-77-9 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-[5-(4-fluorophenyl)-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-, dimethanesulfonate (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Benzimidazol-2-amine, 6-(5-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-1H-imidazol-4-yl)-1-[(1,1-dimethylethyl)sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ACCESSION NUMBER: 2004:143142 CAPLUS
 DOCUMENT NUMBER: 140:199326

TITLE: Preparation of benzimidazoles and benzothiazoles as inhibitors of p-38 map kinase for treating metastasis or rheumatoid arthritis

INVENTOR(S): Bonjouklian, Rosanne; De Diego Gomez, Jose Eugenio; De Dios, Alfonso; Handouchi, Chafiq; Handouchi, Li; Tiechaor Lopez De Uralde Garmendia, Beatriz; Vieth, Michal; York, Jeremy; Schulenburg, Dally; Robert Dean; Del Prado Catalina, Miriam Filadelfia; Jaramillo, Carlos; Martin Cabrejas, Luisa Maria; Montero Salgado, Carlos; Pleite, Sheila; Sanchez-Martinez, Concepcion; Shephard, Timothy Alan; Wikle, James Howard

PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 127 pp.

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014900	A1	20040219	WO 2003-US19890	20030731
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003256297	A1	20040225	AU 2003-256297	20030731
EP 1554272	A1	20050720	EP 2003-784749	20030731
EP 1554272	B1	20060125		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 343572	T	20061115	AT 2003-784749	20030731
US 2005272791	A1	20051208	US 2005-522227	20050125
PRIORITY APPLN. INFO.:			EP 2002-380178	A 20020809
			US 2002-421939P	P 20021028
			WO 2003-US19890	W 20030731

OTHER SOURCE(S): MARPAT 140:199326

GI

Clipped app

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The present invention provides benzimidazoles and benzothiazoles (shown as I; W = imidazolyl, oxazolyl, pyrazolyl, oxopyrazolinyl, thiazolyl, 1,2,3-triazolyl, or imidazo[2,1-b]benzothiazolyl; X = NR4, S; R5 = halo, H, NR9R10; addnl. details are given in the claims; e.g. II) as p-38 map kinase inhibitors. The disclosed compds. inhibit p-38 kinase and are useful in the treatment of metastasis or rheumatoid arthritis. All exemplified I inhibit the p38 kinase enzyme with an IC50 of at least 5 μM. Four exemplified I were tested and found to suppress TNF-α in vitro with an IC50 < 100 nM; three of these suppressed TNF-α in vivo in mice with an IC50 < 100 mg/kg. Treatment of rats with II produced a dose-dependent inhibition of TNF-α synthesis, as measured in the synovial lavage fluid; the TME050 = 10 mg/kg, II caused 54%, 73%, and 95% inhibition of lung metastasis formation for the 3, 10, and 30 mg/kg dose levels, resp., in the B16F10 melanoma lung metastasis model. II showed excellent dose-dependent activities against p38 MAPK in tumors harvested 2.5 h after dosing, seen as a dose-dependent inhibition of MAPKAP-K2 phosphorylation. II exhibited time- and dose-dependent inhibition of MAPKAP-K2 phosphorylation in P815 tumors in vivo. At all doses of II in a rat collagen induced arthritis efficacy model, there was a significant reduction in ankle diameter with a maximum reduction of 46% at 30 mg/kg; prednisolone reduced the inflammation to pre-arthritis levels. Although the methods of preparation are not claimed, preparative procedures and/or characterization data are given for 19 intermediates and 25+ examples of I. For example, 1-isopropylsulfonyl-2-amino-6-(2-(thien-2-yl)-3-(phenyl)imidazol-4-yl)benzimidazole methanesulfonate was prepared in 97% yield by cyclizing thiophene-2-carboxaldehyde with 1-isopropylsulfonyl-2-amino-6-(a-(tert-butylsulfonyl)oxy-a-(phenyl)acetyl)benzimidazole in HOAc in the presence of Cu(OAc)2 and NH4OAc.

IT 660432-27-9P, 1-isopropylsulfonyl-2-amino-6-[1-benzyl-5-(2,4-difluorophenyl)-2-(methyl)imidazol-4-yl]benzimidazole 660432-69-9P

- 1-isopropylsulfonyl-2-amino-6-[2-(thien-2-yl)-3-(phenyl)imidazol-4-yl]benzimidazole 660432-74-6P, 1-isopropylsulfonyl-2-amino-6-(2-(5-nitrothien-2-yl)-5-(phenyl)imidazol-4-yl)benzimidazole 660432-90-6P,

- 1-isopropylsulfonyl-2-amino-6-[2-(1-(tert-butoxycarbonyl)piperidin-4-yl)-5-(4-fluorophenyl)imidazol-4-yl]benzimidazole 660432-91-7P,


- 1-isopropylsulfonyl-2-amino-6-[2-(1-(benzyloxycarbonyl)piperidin-4-yl)-5-

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (phenyl)imidazol-4-yl]benzimidazole 660433-80-7P,
 1-isopropylsulfonyl-2-amino-6-[2-(2,4-difluorophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660433-82-9P, 1-Cyclopentylsulfonyl-2-amino-6-[2-(2,4-difluorophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660433-93-2P, 1-isopropylsulfonyl-2-amino-6-[2-isopropyl-5-(phenyl)imidazol-4-yl]benzimidazole 660433-95-4P, 1-isopropylsulfonyl-2-amino-6-[2-isopropyl-5-(phenyl)imidazol-4-yl]benzimidazole 660434-35-5P 660434-36-6P 660434-54-8P, 1-isopropylsulfonyl-2-amino-6-[1-cyclohexyl-4-(phenyl)imidazol-3-yl]benzimidazole 660434-58-2P, 1-isopropylsulfonyl-2-amino-6-[1-(4-(N-(tert-butoxycarbonyl)amino)cyclohexyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660434-59-3P, 1-isopropylsulfonyl-2-amino-6-[1-(1,4-dioxaspiro[4.5]decan-8-yl)-4-(phenyl)imidazol-5-yl]benzimidazole 660434-73-1P, 1-isopropylsulfonyl-2-amino-6-[1-(4-methoxybenzyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660434-87-7P, 1-isopropylsulfonyl-2-amino-6-[1-cyclopentyl-4-(2-fluorophenyl)imidazol-5-yl]benzimidazole 660435-03-0P, 1-isopropylsulfonyl-2-amino-6-[1-(p-nitrophenyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660435-18-7P, 1-isopropylsulfonyl-2-amino-6-[2-(piperidin-4-yl)-5-(phenyl)imidazol-4-yl]benzimidazole 660435-21-2P, 1-isopropylsulfonyl-2-amino-6-[1-(piperidin-4-yl)-4-(phenyl)imidazol-5-yl]benzimidazole 660435-27-9P, 1-isopropylsulfonyl-2-amino-6-[1-(4-oxocyclohexyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660435-39-2P, 1-isopropylsulfonyl-2-amino-6-[1-(2-benzylamino-6-(4-(phenyl)imidazol-5-yl)benzimidazole 660435-45-0P, 1-isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-bromo-4-(2-fluorophenyl)imidazol-5-yl]benzimidazole 660435-46-1P, 1-isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-(4-chlorophenyl)-4-(2-fluorophenyl)imidazol-5-yl]benzimidazole 660435-50-7P, 1-isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-(trimethylsilyl)ethynyl)-4-(2-fluorophenyl)imidazol-5-yl]benzimidazole 660435-53-0P, 1-isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-(ethynyl)-4-(2-fluorophenyl)imidazol-5-yl]benzimidazole 660435-63-2P, 1-isopropylsulfonyl-2-amino-6-[1-cyclohexyl-2-bromo-4-phenylimidazol-5-yl]benzimidazole 660435-73-3P, 2-Amino-6-[1-cyclohexyl-4-(phenyl)imidazol-5-yl]benzothiazole 660435-95-0P, 2-Chloro-6-[1-cyclohexyl-4-(phenyl)imidazol-5-yl]benzothiazole 660435-98-0P, RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactants or reagent); USES (Uses) (drug candidate; prepn. of benzimidazoles and benzothiazoles as inhibitors of p-38 map kinase for treating metastasis or rheumatoid arthritis)


RN 660432-27-9 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-(5-(2,4-difluorophenyl)-2-methyl-1-(phenylmethyl)-1H-imidazol-4-yl)-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)


Karen Cheng




RN 660432-69-9 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-[5-phenyl-2-(2-thienyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 660432-74-6 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-[2-(5-nitro-2-thienyl)-5-phenyl-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 660432-84-8 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-[2-(4-nitrophenyl)-5-phenyl-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 660432-90-6 CAPLUS
CN 1-Piperidinocarboxylic acid, 4-[(2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl)-5-(4-fluorophenyl)-1H-imidazol-2-yl]-, 1,1-dimethyl-ethyl ester (9CI) (CA INDEX NAME)




RN 660432-91-7 CAPLUS
CN 1-Piperidinocarboxylic acid, 4-[(2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl)-5-phenyl-1H-imidazol-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 660433-80-7 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 660433-82-9 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-[(cyclopentylsulfonyl)-6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 660433-93-2 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[5-(4-fluorophenyl)-2-(1-methylethyl)-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 660433-95-4 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(1-methylethyl)-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 660434-35-5 CAPLUS
CN 1-Piperidinocarboxylic acid, 4-[(5-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-4-phenyl-1H-imidazol-1-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 660434-36-6 CAPLUS
CN 1-Piperidinocarboxylic acid, 4-[(5-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-4-(4-fluorophenyl)-1H-imidazol-1-yl)-, ethyl ester (9CI) (CA INDEX NAME)







RN 660435-93-8 CAPLUS
CN 2-Benzothiazolamine, 6-(5-phenyl-1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)




RN 660435-96-1 CAPLUS
CN 2-Benzothiazolamine, 6-(1-cyclohexyl-4-phenyl-1H-imidazol-5-yl)-N-ethyl- (9CI) (CA INDEX NAME)



RN 660435-97-2 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-(5-phenyl-1H-1,2,3-triazol-4-yl)- (9CI) (CA INDEX NAME)



RN 660435-98-3 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-(3-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)




RN 660435-99-4 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 660433-80-7

CMF C25 H21 F2 N5 O2 S




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 660866-17-1 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(fluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 660866-16-0
CMF C25 H22 F5 N5 O2 S
CCI IDS



D1-F



CM 2


CRN 75-75-2
CMF C H4 O3 S




IT 660435-35-2, 1-Isopropylsulfonyl-2-amino-6-[2-(2-fluoro-4-nitrophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660434-12-8, 1-isopropylsulfonyl-2-amino-6-[(2-(trimethylsilyl)ethoxy)methyl]-2-formyl-5-(phenyl)imidazol-4-yl]benzimidazole 660435-62-1, 1-isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-(2-fluorophenyl)-2-nitro-1H-imidazol-5-yl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of benzimidazoles and benzothiazoles as inhibitors of p-38 map kinase for treating metastasis or rheumatoid arthritis)


RN 660435-35-2 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2-fluoro-4-nitrophenyl)-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 660434-12-8 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-formyl-5-phenyl-1-[(2-(trimethylsilyl)ethoxy)methyl]-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 660435-62-1 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[1-cyclopropyl-2-(2-fluorophenyl)-2-nitro-1H-imidazol-5-yl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




IT 660432-22-4P, 1-Isopropylsulfonyl-2-amino-6-[(2-(trimethylsilyl)ethoxy)methyl]-2-formyl-4-(phenyl)imidazol-5-yl]benzimidazole 660432-25-7P, 1-Isopropylsulfonyl-2-amino-6-[1-benzyl-5-(3,5-difluorophenyl)-2-(2,4-difluorophenyl)imidazol-4-

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 yl]benzimidazole 660434-14-0F, 1-isopropylsulfonyl-2-amino-6-[1-[2-(trimethylsilyl)ethoxy]methyl]-2-[(piperidin-1-yl)methyl]-5-(phenyl)imidazol-4-yl]benzimidazole 660434-20-8P,
 1-isopropylsulfonyl-2-amino-6-[2-[(N-[2-(piperidin-1-yl)ethyl]amino)methyl]-5-(phenyl)-1-[(2-(trimethylsilyl)ethoxy)methyl]imidazol-4-yl]benzimidazole 660434-23-1P, 1-isopropylsulfonyl-2-amino-6-[1-[(2-(trimethylsilyl)ethoxy)methyl]-2-[(ethoxycarbonyl)ethen-2-yl]-5-(phenyl)imidazol-4-yl]benzimidazole 660434-24-2P,
 1-isopropylsulfonyl-2-amino-6-[1-[(2-(trimethylsilyl)ethoxy)methyl]-2-[(ethoxycarbonyl)ethen-2-yl]-5-(phenyl)imidazol-4-yl]benzimidazole 660435-44-9P, 1-isopropylsulfonyl-2-chloro-6-[1-(4-methoxyethyl)-4-(phenyl)imidazol-5-yl]benzimidazole
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prep. of benzimidazoles and benzothiazoles as inhibitors of p-38 map kinase for treating metastasis or rheumatoid arthritis)


RN 660432-22-4 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-(2-formyl-4-phenyl-1-[2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)-1-[(1-methylethyl)sulfonyl]-(9CI) (CA INDEX NAME)




RN 660432-25-7 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[2-(2,4-difluorophenyl)-5-(3,5-difluorophenyl)-1-(phenylmethyl)-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-(9CI) (CA INDEX NAME)




RN 660434-14-0 CAPLUS

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-[5-phenyl-2-[(1-piperidinylmethyl)-1-[(2-(trimethylsilyl)ethoxy)methyl]-1H-imidazol-4-yl]-(9CI) (CA INDEX NAME)




RN 660434-20-8 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-[5-phenyl-2-[(1-piperidinylmethyl)-1-[(2-(trimethylsilyl)ethoxy)methyl]-1H-imidazol-4-yl]-(9CI) (CA INDEX NAME)



RN 660434-23-1 CAPLUS

CN 1H-Imidazole-2-acetic acid, 4-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-a-methylene-5-phenyl-1-[(2-(trimethylsilyl)ethoxy)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 660434-24-2 CAPLUS

CN 1H-Imidazole-2-acetic acid, 4-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-a-methylene-5-phenyl-1-[(2-(trimethylsilyl)ethoxy)methyl]-, ethyl ester (9CI) (CA INDEX NAME)


possible
103- need
check
date

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 660435-44-9 CAPLUS

CN 1H-Benzimidazole, 2-chloro-6-[1-[(4-methoxyphenyl)methyl]-4-phenyl-1H-imidazol-5-yl]-1-[(1-methylethyl)sulfonyl]-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003-396884 CAPLUS

DOCUMENT NUMBER: 138:401735

TITLE: Preparation of phenyl substituted triazoles as selective inhibitors of ALK5 kinase

INVENTOR(S): Gaster, Lazamie Mary; Harling, John David; Heer, Jag Paul; Heightman, Thomas Daniel; Payne, Andrew Hele Smithkline Beecham Corporation, USA

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003042211	A1	20030522	WO 2002-EP13482	20021114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HD, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MC, MN, MW, MX, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TH, TN, TR, TT, TZ, UN, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, MI, MR, NE, SN, TD, TG				
CA 2467267	A1	20030522	CA 2002-2467267	20021114
EP 1444232	A1	20040911	EP 2002-803039	20021114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002014160	A	20040928	BR 2002-14160	20021114
HU 200402227	A2	20050228	HU 2004-2227	20021114
CN 1608065	A	20050420	CN 2002-825914	20021114
JP 2005518352	T	20050623	JP 2003-544047	20021114
US 2005014938	A1	20050120	US 2004-495414	20040513
NO 2004002244	A	20040713	NO 2004-2244	20040528
PRIORITY APPLN. INFO.:			GB 2001-27430	A 20011115
OTHER SOURCE(S):			WO 2002-EP13482	W 20021114

GI MARPAT 138:401735



AB The title compds. [I: R1 = (un)substituted naphthyl, Ph, or Ph or pyridyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said

Date to beat 10/28/02

10522227a

103



L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
cyclic ring optionally contains up to three heteroatoms, independently selected from N, O and S; R2 and R3 = H, alkyl, alkoxy, etc.; two of X2 and X3 = N and the other = NR4 (wherein R4 = H, alkyl, cycloalkyl, etc.); which are inhibitors of the transforming growth factor, TGF- β signaling pathway, in particular, the phosphorylation of smad2 or smad3 by the type I or activin-like kinase-5 (ALK-5) receptor were prep'd. Thus, heating a soln. of 6-(3-chlorophenyl)ethylcinnolin-1,2,4-triazole[1,5-s]azepidine (prep. given) and azidotrimethylsilane in DMF at 130°C for 19 h afforded 35% II. The compds. I generally show ALK5 receptor modulator activity having IC50 values in the range of 0.0001 to 10 μ M.

IT 528892-29-7P

PL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of Ph substituted triazoles as selective inhibitors of ALK5 kinase)

RN 528892-29-7 CAPLUS
CN 1H-Benzimidazole, 6-[5-(3-chlorophenyl)-1H-1,2,3-triazol-4-yl]-1-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT:


6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

need find GB application?

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
ACCESSION NUMBER: 2002:350613 CAPLUS
DOCUMENT NUMBER: 137:353066
TITLE: Preparation of nitrogenous fused-ring compound having pyrazolyl group as substituents as inhibitors of activation of signal transduction and activation of transcription (STAT6) protein
INVENTOR(S): Yoshida, Ichiro; Yoneda, Naoki; Ohashi, Yoshiaki; Suzuki, Shuichi; Miyamoto, Mitsuaki; Miyazaki, Futoshi; Seshimo, Hidenori; Kamata, Junichi; Takase, Yasutaka; Shirato, Manabu; Shimokubo, Daiya; Sakuma, Yoshinori; Yokohama, Hiromitsu
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 1006 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088107	A1	20021107	WO 2002-JP4156	20020425
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1382603	A1	20040121	EP 2002-722791	20020425
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, AL, TR				
US 7074801	BI	20060711	US 2003-475585	20031023
PRIORITY APPN. INFO.: JP 2001-129959			JP 2001-129959	A 20010426
OTHER SOURCE(S): MARPAT 137:353066			WO 2002-JP4156	W 20020425
GI				

need find GB application?



AB The 4-(N-containing fused aromatic heterocyclyl)pyrazoles (I) or salts thereof,

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
or hydrates of either [X = a nitrogenous fused arom. heterocyclic group, e.g., imidazo[1,2-b]pyridine, having (R4)n as a substituent, wherein n = an integer of 0-3; R4 = H, halo, cyano, OH, NH2, Cl-6 alkyl, halo-Cl-6 alkyl, C2-6 alkyl, Cl-6 alkylsulfonyl, Cl-6 alkylsulfonylamino, Cl-6 alkylsulfamyl, N-mono- or N,N-di(Cl-6 alkyl)amino, Cl-6 alkyl, Cl-6 alkylsulfonyl, CONH2, etc.; N = C3-8 cycloalkyl, C4-8 cycloalkenyl, 5- to 14-membered nonarom. or arom. heterocyclyl, C6-14 arom. hydrocarbyl, benzene- or 5- or 6-membered arom. heterocyclyl-fused 5- to 7-membered nonarom. ring group; Z = H, NH2, halo, HO, NO2, cyano, N3, CHO, HOMH, SO2NH2, guanidino, oxo, C2-6 alkyl, Cl-6 alkoxy, etc.; R1 = H, halo, HO, NO2, cyano, halo-Cl-6 alkyl, hydroxyl- or cyano-Cl-6 alkyl, C2-6 alkenyl, etc.; R2 = H, pyrazolyl; R3 = H, halo, cyano, NH2, Cl-4 alkyl, halo-Cl-4 alkyl] are prep'd. These compds. are inhibitors of STAT6 protein activation and IL-4 and/or IL-13 signal transduction and are useful for prevention and/or treatment of diseases on which the inhibition of STAT6 activation and/or IL-4 and/or IL-13 signal transduction is effective. The diseases include allergy, allergic rhinitis, bronchial asthma, atopic dermatitis, poliomyelitis, digestive tract allergy, urticaria, hypersensitivity pneumonia, lung aspergillosis, eosinophil leukemia, parasitic infection, eosinophilia, eosinophil pneumonia, eosinophil gastroenteritis, autoimmune disease, systemic lupus erythematosus, virus infection, bacteria infection, obesity, overeating (hyperphagia), malignant tumor, and acquired immunodeficiency syndrome (AIDS). Thus, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile was coupled with 6-[3-(4-fluorophenyl)-1-trityl-1H-pyrazolyl]-3-iodomidazo[1,2-a]pyridine in the presence of tetrakis(triphenylphosphine)palladium and K3PO4 in DMF at 75° for 3 h followed by treating a soln. of the coupling product in THF and MeOH with 5 N aq. HCl to give 4-[6-(3-(4-fluorophenyl)-1H-pyrazolyl)imidazo[1,2-a]pyridin-3-yl]benzonitrile dihydrochloride (II). II showed IC50 of <10 nM for inhibiting the IL-4-induced induction of alkaline phosphatase in human embryonic kidney cell transfected with STAT gene and STAT reporter gene.

IT 474695-63-1P 474695-71-4P 474695-74-4P

474695-75-5P 474695-76-6P 474695-77-7P

474695-78-8P 474695-79-9P 474695-80-2P

474695-81-3P 474701-68-3P 474701-69-4P

474701-70-7P 474701-71-8P 474701-72-9P

474706-30-4P 474706-31-5P


PL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (N-containing heterocyclyl)pyrazole as inhibitors of activation of STAT6 protein and/or IL-4 and/or IL-13 signal transduction as preventives and/or remedies of diseases)

RN 474695-63-1 CAPLUS


CN 1H-Benzimidazole, 1-(4-fluorophenyl)-6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● 2 HCl

RN 474695-71-1 CAPLUS
CN 1H-Benzimidazole-2-amine, 1-(4-fluorophenyl)-6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



$X = N(R^4)$
 $R^4 = \text{phenyl}$.


RN 474695-74-4 CAPLUS
CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Karen Cheng

10522227a

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




needs to be
 $H_2(C_5-C_6\text{ cycloalkyl})\text{sulfonfyl}$
 $(C_3-C_6\text{ cycloalkyl})\text{sulfonfyl}$
 $(C_1-C_4\text{ alkyl})N\text{-sulfonfyl.}$


RN 474695-75-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-[6-[3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, trihydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 474695-77-7 CAPLUS
CN 3-Pyridinecarbonitrile, 6-[6-[3-(4-cyanophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, trihydrochloride (9CI) (CA INDEX NAME)




RN 474695-76-6 CAPLUS
CN 3-Pyridinecarbonitrile, 6-[6-[3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, trihydrochloride (9CI) (CA INDEX NAME)




RN 474695-78-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-[6-[3-(4-cyanophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-N,N-dimethyl-, (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 474695-79-9 CAPLUS
CN 3-Pyridinecarbonitrile, 6-[6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, trihydrochloride (9CI) (CA INDEX NAME)


L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 474695-81-3 CAPLUS
CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-[5-(methylsulfonyl)-2-thienyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl
RN 474695-80-2 CAPLUS
CN 3-Pyridinecarbonitrile, 6-[6-[3-(3-cyanophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl
RN 474701-69-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-N,N-dimethyl-, (9CI) (CA INDEX NAME)


Karen Cheng



RN 474701-69-4 CAPLUS
CN Morpholine, 4-[(6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl)-3-pyridinyl]carbonyl-, dihydrochloride (9CI) (CA INDEX NAME)




RN 474701-70-7 CAPLUS
CN Pyrrolidine, 1-[(6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl)-3-pyridinyl]carbonyl-3-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 474701-71-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-6-[6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-N-methyl-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 474701-72-9 CAPLUS
CN 1H-Benzimidazole, 1-(5-chloro-2-pyridinyl)-6-[3-(2,6-difluorophenyl)-1H-pyrazol-4-yl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 474706-30-4 CAPLUS
CN 1H-Benzimidazole, 1-(5-chloro-2-pyridinyl)-6-(3-(2,4-difluorophenyl)-1H-pyrazol-4-yl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 474706-31-5 CAPLUS
CN 1H-Benzimidazole, 1-(5-chloro-2-pyridinyl)-6-[3-(2-fluorophenyl)-1H-pyrazol-4-yl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

IT 474701-59-2P 474701-60-5P 474701-61-6P
474701-62-7P 474701-63-8P 474706-26-8P
474706-27-9P 474707-04-5P 474707-06-7P
474709-99-4P 474710-00-4P 474711-65-4P
474711-70-1P 474711-73-4P 474711-75-6P
474711-76-7P 474711-77-8P 474711-78-9P
474711-79-0P 474711-82-5P 474711-84-7P
474712-65-7P 474712-66-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (N-containing heterocyclic)pyrazole as inhibitors of activation of STAT6 protein and/or IL-4 and/or IL-13 signal transduction as preventives and/or remedies of diseases)

RN 474701-59-2 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[6-[3-(4-fluorophenyl)-1H-benzimidazol-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)




10522227a

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 474701-60-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)



RN 474701-61-6 CAPLUS

CN 3-Pyridinecarboxamide, 6-[6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 474701-62-7 CAPLUS

CN Morpholine, 4-[(6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl)-3-pyridinyl]carbonyl- (9CI) (CA INDEX NAME)


possible
102 → ask if CPh₃

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 474701-63-8 CAPLUS

CN Pyrrolidine, 1-[(6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl)-3-pyridinyl]carbonyl-3-methoxy- (9CI) (CA INDEX NAME)





RN 474706-26-8 CAPLUS

CN 1H-Benzimidazole, 1-(5-chloro-2-pyridinyl)-6-[3-(2,4-difluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)


L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
1H-pyrazol-4-yl)-1H-benzimidazol-1-yl)methyl ester (9CI) (CA INDEX NAME)



RN 474706-27-9 CAPLUS

CN 1H-Benzimidazole, 1-(5-chloro-2-pyridinyl)-6-[3-(2-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 474709-99-4 CAPLUS

CN 1H-Benzimidazole, 5-[3-(2,6-difluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

RN 474707-04-5 CAPLUS
CN 1H-Benzimidazole, 5-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

RN 474707-06-7 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, [6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-


Karen Cheng

X = N⁺R¹, R¹ = H
R¹ = C₁₋₆ alkyl
W = IV¹
R² = H
R³ = phenyl.

10522227a


L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



RN 474711-70-1 CAPLUS

CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 474711-73-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-[6-[3-[4-(methylthio)phenyl]-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)


L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



RN 474711-75-6 CAPLUS

CN 3-Pyridinecarboxamide, 6-[6-[3-[4-(methylsulfinyl)phenyl]-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 474711-76-7 CAPLUS

CN 3-Pyridinecarboxamide, 6-[6-[3-[4-(methylsulfonyl)phenyl]-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)


L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



RN 474711-77-8 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[6-[3-[4-(methylthio)phenyl]-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 474711-78-9 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[6-[3-[4-(methylsulfonyl)phenyl]-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)


L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



RN 474711-79-0 CAPLUS


CN 3-Pyridinecarbonitrile, 6-[6-[3-[4-cyanophenyl]-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 474711-82-5 CAPLUS

CN 3-Pyridinecarboxamide, 6-[6-[3-[4-cyanophenyl]-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Karen Cheng




RN 474711-7 CAPLUS
 CN 3-Pyridinecarboxonitrile, 6-[6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 474712-65-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-6-[6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 474712-66-8 CAPLUS
 CN 1H-Benzimidazole, 1H-[5-chloro-2-pyridinyl]-6-[3-(2,6-difluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1996:607249 CAPLUS
 DOCUMENT NUMBER: 125:247806
 TITLE: Preparation of pyrazole derivatives as antiviral agents
 INVENTOR(S): Kai, Yasunobu; Tsuruoka, Akihiko; Yanagisawa, Manabu; Takeuchi, Hitoshi; Taniguchi, Hirouki; Tanabe, Kazunori; Yamamoto, Motosuke
 PATENT ASSIGNEE(S): Eisai Co Ltd, Japan
 SOURCE: Jpn. Kokai Tokyo Koho, 38 pp.
 CODEN: JXXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09183707	A	19960716	JP 1994-328129	19941228
JP 3734180	B2	20060111	JP 1994-328129	19941228

PRIORITY APPLN. INFO.: MARPAT 125:247806
 OTHER SOURCE(S): MARPAT 125:247806
 GI For diagram(s), see printed CA Issue.
 AB The title compds. I [ring A is (un)substituted aromatic ring (which may have one or more hetero atoms), etc.; R1 = alkyl, etc.; R2 = H, etc.; R3 = H, H2O, etc.] are prepared. The title compound II (preparation given) in vitro showed IC₅₀ of <0.016 µg/mL against herpes simplex virus type 1.
 191865-74-7P 191865-75-8P 191865-76-9P
 191865-77-0P 191865-82-7P 191865-84-9P
 191865-86-1P 191865-90-7P 191865-94-1P
 191866-01-3P 191866-04-6P 191866-07-9P
 191866-22-8P 191866-30-8P 191866-39-7P
 191866-49-9P 191866-56-8P 191866-70-6P
 191866-72-8P 191866-74-0P 191866-79-4P
 191866-79-5P 191866-80-8P 191867-98-1P
 Hu-BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPM (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); USES (Uses); (preparation of pyrazole derivs. as antiviral agents)
 RN 191865-74-7 CAPLUS
 CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 181865-75-8 CAPLUS
 Karen Cheng


L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Benzimidazole, 5-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 181865-76-9 CAPLUS
 CN 1H-Benzimidazole, 5-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 181865-77-0 CAPLUS
 CN 1H-Benzimidazole, 1-ethyl-6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 181865-82-7 CAPLUS
 CN 1H-Benzimidazole, 6-[3-(2,4-difluorophenyl)-1H-pyrazol-4-yl]-1-methyl- (9CI) (CA INDEX NAME)

10522227a


L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 181865-84-9 CAPLUS
CN 1H-Benzimidazole, 6-[3-(2-fluorophenyl)-1H-pyrazol-4-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 181865-86-1 CAPLUS
CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 181865-90-7 CAPLUS
CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-[(2-phenylmethoxy)ethoxy]methyl- (9CI) (CA INDEX NAME)


$X = N R^4$, $R^4 = H$
(methyl)

$R^1 = H$
 $R^3 =$ phenyl subst. w/
2 halogens.


L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 181865-94-1 CAPLUS
CN Ethanol, 2-[(6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl)methoxy]- (9CI) (CA INDEX NAME)




RN 181866-01-3 CAPLUS
CN 1H-Benzimidazole, 1-methyl-6-[3-(4-nitrophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 181866-04-6 CAPLUS
CN Benzenamine, 4-[(1-methyl-1H-benzimidazol-6-yl)-1H-pyrazol-3-yl]- (9CI)


L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 181866-07-9 CAPLUS
CN 1H-Benzimidazole, 6-[3-(3,4-dimethoxyphenyl)-1H-pyrazol-4-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 181866-22-8 CAPLUS
CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-[(2-phenylmethoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 181866-30-8 CAPLUS
CN 1H-Benzimidazole-1-ethanol, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

$R^3 =$ phenyl subst.
w/ alkoxy.


L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 181866-39-7 CAPLUS
CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-(2-propoxyethyl)- (9CI) (CA INDEX NAME)



RN 181866-49-9 CAPLUS
CN 1H-Benzimidazole, 1-[(2-ethylthio)ethyl]-6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 181866-56-8 CAPLUS
CN 1H-Benzimidazole-1-acetic acid, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-ethyl ester (9CI) (CA INDEX NAME)

Karen Cheng

1052227a

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 181866-70-6 CAPLUS
CN 1H-Benzimidazole, 1-methyl-6-[3-(2-thienyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

R₃ = thiienyl


RN 181866-72-8 CAPLUS
CN 1H-Benzimidazole, 6-[3-(4-methoxyphenyl)-1H-pyrazol-4-yl]-1-methyl- (9CI)
(CA INDEX NAME)

RN 181866-74-0 CAPLUS
CN 1H-Benzimidazole, 6-[3-(4-bromophenyl)-1H-pyrazol-4-yl]-1-methyl- (9CI)
(CA INDEX NAME)


L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 181866-78-4 CAPLUS
CN 1H-Benzimidazole, 6-[3-(2-bromophenyl)-1H-pyrazol-4-yl]-1-methyl- (9CI)
(CA INDEX NAME)



RN 181866-79-5 CAPLUS
CN 1H-Benzimidazole, 6-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-1-methyl- (9CI)
(CA INDEX NAME)




RN 181866-80-8 CAPLUS
CN Benzenamine, N,N-dimethyl-4-[4-(1-methyl-1H-benzimidazol-6-yl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)


L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 181867-98-1 CAPLUS
CN 1H-Benzimidazole, 1-methyl-6-[3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1-[(2-(trimethylsilyl)ethoxy)methyl]-1H-pyrazol-4-yl]-1-(triphenylmethyl)- (9CI)
(CA INDEX NAME)




RN 181866-95-5 CAPLUS
CN 1H-Benzimidazole, 6-[5-(4-fluorophenyl)-1-[(2-(trimethylsilyl)ethoxy)methyl]-1H-pyrazol-4-yl]-1-(triphenylmethyl)- (9CI)
(CA INDEX NAME)



IT 181865-90-5P 181866-94-4P 181866-95-5P
RN - RCT - (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or Reagent)
(preparation of pyrazole derivs. as antiviral agents)


RN 181865-90-5 CAPLUS
CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-methyl- (9CI)
(CA INDEX NAME)



RN 181866-94-4 CAPLUS
Karen Cheng

10522227a


Search for



w/ W defined

R5

X



chain nodes :

49 66 67 69 75 81

ring nodes :

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46

54	55	56	57	58	59	60	61	62	63	70	71	72	76	77	78	79						
----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	--	--	--	--	--	--

chain bonds :

21-49 50-69 51-81 52-66 53-67 71-75

ring bonds :

1-2	1-5	2-3	3-4	4-5	6-7	6-10	7-8	8-9	9-10	11-12	11-15	12-13	13-14									
14-15	16-17	16-20	17-18	18-19	19-20	21-22	21-25	22-23	23-24	24-25	26-27											
26-30	27-28	28-29	29-30	31-32	31-35	32-33	33-34	34-35	36-37	36-40	37-38											
38-39	39-40	50-51	50-55	51-52	52-53	53-54	54-55	54-70	55-72	56-60	56-57											
56-76	57-58	57-79	58-59	58-61	59-60	59-63	61-62	62-63	70-71	71-72	76-77											
77-78	78-79																					

exact/norm bonds :

1-2	1-5	2-3	3-4	4-5	6-7	6-10	7-8	8-9	9-10	11-12	11-15	12-13	13-14									
14-15	16-17	16-20	17-18	18-19	19-20	21-22	21-25	21-49	22-23	23-24	24-25	26-27										
26-27	26-30	27-28	28-29	29-30	31-32	31-35	32-33	33-34	34-35	36-37	36-40	37-38										
37-38	38-39	39-40	50-69	51-81	52-66	53-67	54-70	55-72	56-60	56-57	56-76											
57-58	57-79	58-59	58-61	59-60	59-63	61-62	62-63	70-71	71-72	71-75	76-77											
77-78	78-79																					

normalized bonds :

50-51 50-55 51-52 52-53 53-54 54-55

isolated ring systems :

containing 50 :

G1:H,CH3

G2:S,N


G3:X,H,CH3,N

Karen Cheng

10522227duprem

\Rightarrow

Uploading C:\Program Files\Stnexp\Queries\10522227c.str



w/ R⁵




X

\hat{W} and R^3
defined but w/
diff.

diff.
point

for

R^3 = three gal



attach here.

chain nodes :

49 66 67 69 75 81 96 97 98 100 101 102 103 104 105

ring nodes :

chain bonds :

5-96 10-97 12-98 16-100 21-49 25-101 29-102 32-103 39-104 50-69 51-81
52-66 53-67 62-105 71-75

ring bonds :

exact/norm bonds :

exact/norm bonds :
 1-2 1-5 2-3 3-4 4-5 5-96 6-7 6-10 7-8 8-9 9-10 10-97 11-12 11-15
 12-13 12-98 13-14 14-15 16-17 16-20 16-100 17-18 18-19 19-20 21-22 21-25
 21-49 22-23 23-24 24-25 25-101 26-27 26-30 27-28 28-29 29-30 29-102
 31-32 31-35 32-33 32-103 33-34 34-35 36-37 36-40 37-38 38-39 39-40
 39-104 50-69 51-81 52-66 53-67 54-70 55-72 56-60 56-57 56-76 57-58 57-79
 Käfēñ9Chéñg61 59-60 59-63 61-62 62-63 62-105 70-71 71-72 71-75 76-77
 77-78 78-79 83-84 83-87 84-85 85-86 86-87

10522227duprem

normalized bonds :
50-51 50-55 51-52 52-53 53-54 54-55 88-89 88-93 89-90 90-91 91-92 92-93
isolated ring systems :
containing 50 :

G1:H,CH3

G2:S,N

G3:X,H,CH3,N

G4:[*1],[*2],[*3],[*4],[*5],[*6],[*7],[*8],[*9]

G5:[*10],[*11]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
38:Atom 39:Atom 40:Atom 49:CLASS 50:Atom 51:Atom 52:Atom 53:Atom 54:Atom
55:Atom 56:Atom 57:Atom 58:Atom 59:Atom 60:Atom 61:Atom 62:Atom 63:Atom
66:CLASS 67:CLASS 69:CLASS 70:CLASS 71:CLASS 72:CLASS 75:CLASS 76:Atom
77:Atom 78:Atom 79:Atom 81:CLASS 83:Atom 84:Atom 85:Atom 86:Atom 87:Atom
88:Atom 89:Atom 90:Atom 91:Atom 92:Atom 93:Atom 96:CLASS 97:CLASS 98:CLASS
100:CLASS 101:CLASS 102:CLASS 103:CLASS 104:CLASS 105:CLASS

L8 STRUCTURE UPLOADED

=> d

L8 HAS NO ANSWERS

L8 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 18:21:08 ON 08 FEB 2007)

FILE 'REGISTRY' ENTERED AT 18:21:37 ON 08 FEB 2007

L1 STRUCTURE UPLOADED

L2 43 S L1

L3 898 S L1 FULL

FILE 'CAPLUS' ENTERED AT 18:22:06 ON 08 FEB 2007

L4 43 S L3

FILE 'STNGUIDE' ENTERED AT 18:22:24 ON 08 FEB 2007

FILE 'REGISTRY' ENTERED AT 18:32:38 ON 08 FEB 2007

L5 STRUCTURE UPLOADED

Karen Cheng

10522227duprem

=> d his

(FILE 'HOME' ENTERED AT 18:21:08 ON 08 FEB 2007)

FILE 'REGISTRY' ENTERED AT 18:21:37 ON 08 FEB 2007
L1 STRUCTURE uploaded

L2 43 S L1
L3 898 S L1 FULL

FILE 'CAPPLUS' ENTERED AT 18:22:06 ON 08 FEB 2007
L4 43 S L3

FILE 'STNGUIDE' ENTERED AT 18:22:24 ON 08 FEB 2007

FILE 'REGISTRY' ENTERED AT 18:32:38 ON 08 FEB 2007
L5 STRUCTURE uploaded
L6 596 S L5 FULL SUB=L3

FILE 'CAPPLUS' ENTERED AT 18:33:19 ON 08 FEB 2007
L7 7 S L6

FILE 'REGISTRY' ENTERED AT 18:37:43 ON 08 FEB 2007
L8 STRUCTURE uploaded
L9 596 S L8 FULL SUB=L3
L10 1192 DUP REM L6 L9 (0 DUPLICATES REMOVED)

FILE 'CAPPLUS' ENTERED AT 18:40:22 ON 08 FEB 2007
L11 7 S L9
L12 7 DUP REM L7 L11 (7 DUPLICATES REMOVED)

=> d ibib abs l12 tot

← prior search
← current search
of structure
current
search
← results
no duplicates